Syntax Research Inc. Sells 14,408 Shares of Zoetis Inc. $ZTS

Syntax Research Inc. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 97.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 302 shares of the company’s stock after selling 14,408 shares during the period. Syntax Research Inc.’s holdings in Zoetis were worth $38,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Global Wealth Strategies & Associates bought a new position in shares of Zoetis in the fourth quarter worth about $25,000. Lodestone Wealth Management LLC bought a new position in shares of Zoetis in the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis in the third quarter worth about $31,000. Holos Integrated Wealth LLC bought a new position in shares of Zoetis in the fourth quarter worth about $32,000. Finally, Board of the Pension Protection Fund bought a new position in shares of Zoetis in the fourth quarter worth about $38,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ZTS shares. Bank of America upped their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, UBS Group dropped their price objective on Zoetis from $136.00 to $130.00 and set a “neutral” rating for the company in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $151.75.

Zoetis Stock Performance

NYSE ZTS opened at $114.22 on Friday. The stock has a market capitalization of $48.05 billion, a PE ratio of 18.97, a P/E/G ratio of 1.77 and a beta of 0.87. The business has a 50 day simple moving average of $119.93 and a two-hundred day simple moving average of $124.79. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a 1-year low of $112.97 and a 1-year high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts predict that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.